PL314603A1 - Substituted n-(indolo-2-carbonyl)-beta-alaninamides and their derivatives as antidiabetic agents - Google Patents
Substituted n-(indolo-2-carbonyl)-beta-alaninamides and their derivatives as antidiabetic agentsInfo
- Publication number
- PL314603A1 PL314603A1 PL96314603A PL31460396A PL314603A1 PL 314603 A1 PL314603 A1 PL 314603A1 PL 96314603 A PL96314603 A PL 96314603A PL 31460396 A PL31460396 A PL 31460396A PL 314603 A1 PL314603 A1 PL 314603A1
- Authority
- PL
- Poland
- Prior art keywords
- alaninamides
- indolo
- carbonyl
- beta
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002223625A CA2223625C (en) | 1995-06-06 | 1995-06-06 | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
PCT/IB1995/000443 WO1996039385A1 (en) | 1995-06-06 | 1995-06-06 | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PL314603A1 true PL314603A1 (en) | 1996-12-09 |
Family
ID=25679897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL96314603A PL314603A1 (en) | 1995-06-06 | 1996-06-04 | Substituted n-(indolo-2-carbonyl)-beta-alaninamides and their derivatives as antidiabetic agents |
Country Status (40)
Country | Link |
---|---|
US (1) | US6297269B1 (xx) |
EP (1) | EP0832066B1 (xx) |
JP (1) | JP3068200B2 (xx) |
CN (1) | CN1374082A (xx) |
AP (2) | AP9600817A0 (xx) |
AT (1) | ATE205477T1 (xx) |
AU (1) | AU700887B2 (xx) |
BG (1) | BG62566B1 (xx) |
BR (1) | BR9602626A (xx) |
CA (1) | CA2223625C (xx) |
CO (1) | CO4700453A1 (xx) |
CZ (1) | CZ289233B6 (xx) |
DE (1) | DE69522718T2 (xx) |
DK (1) | DK0832066T3 (xx) |
DZ (1) | DZ2036A1 (xx) |
ES (1) | ES2161291T3 (xx) |
FI (1) | FI974437A (xx) |
GR (1) | GR3037075T3 (xx) |
HR (1) | HRP960266B1 (xx) |
HU (1) | HUP9601285A3 (xx) |
IL (1) | IL118236A0 (xx) |
IS (1) | IS1846B (xx) |
LV (1) | LV11614B (xx) |
MA (1) | MA23874A1 (xx) |
MX (1) | MX9709874A (xx) |
NO (1) | NO307335B1 (xx) |
NZ (1) | NZ286736A (xx) |
OA (1) | OA10459A (xx) |
PL (1) | PL314603A1 (xx) |
PT (1) | PT832066E (xx) |
RU (1) | RU2159613C2 (xx) |
SG (1) | SG45481A1 (xx) |
SI (1) | SI9600163A (xx) |
SK (1) | SK72096A3 (xx) |
TN (1) | TNSN96075A1 (xx) |
TR (1) | TR199600478A1 (xx) |
TW (1) | TW450961B (xx) |
WO (1) | WO1996039385A1 (xx) |
YU (1) | YU34796A (xx) |
ZA (1) | ZA964646B (xx) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0832066B1 (en) * | 1995-06-06 | 2001-09-12 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
US5952322A (en) * | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
DE69840552D1 (de) | 1997-04-15 | 2009-03-26 | Csir | Verbindungen und Pharmazeutische Zusammensetzungen mit appetitunterdrückender Aktivität |
KR100666591B1 (ko) * | 1997-06-18 | 2007-01-11 | 스미스클라인비이참피이엘시이 | 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료 |
US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
EP1745774A3 (en) | 1997-08-11 | 2007-04-11 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
US6096778A (en) * | 1997-10-07 | 2000-08-01 | Cephalon, Inc. | α-ketoamide multicatalytic protease inhibitors |
US6083944A (en) * | 1997-10-07 | 2000-07-04 | Cephalon, Inc. | Quinoline-containing α-ketoamide cysteine and serine protease inhibitors |
US6150378A (en) * | 1997-10-07 | 2000-11-21 | Cephalon, Inc. | Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors |
UA57811C2 (uk) * | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
CA2319195A1 (en) | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
JP4459441B2 (ja) * | 1998-05-01 | 2010-04-28 | 塩野義製薬株式会社 | sPLA2阻害剤エステル |
EP0978279A1 (en) * | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
US6686335B1 (en) | 1998-09-22 | 2004-02-03 | Cephalon, Inc. | Hydroxamate-containing cysteine and serine protease inhibitors |
ATE494388T1 (de) | 1999-01-13 | 2011-01-15 | Univ New York State Res Found | Neues verfahren zum erschaffen von proteinkinase- inhibitoren |
US6239163B1 (en) | 1999-03-15 | 2001-05-29 | Novo Nordisk A/S | Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine |
US6316489B1 (en) | 1999-03-15 | 2001-11-13 | Novo Nordisk A/S | Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine |
US6410750B1 (en) * | 1999-06-18 | 2002-06-25 | Pfizer Inc. | Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid |
ATE257480T1 (de) * | 1999-09-30 | 2004-01-15 | Pfizer Prod Inc | Bicyclische pyrrolylamide als glycogenphosphorylase-inhibitoren |
GB2396815B (en) | 1999-10-27 | 2004-09-08 | Phytopharm Plc | A composition comprising a pregnenone derivative and an NSAID |
HUP0204278A2 (hu) | 1999-11-04 | 2003-04-28 | Ortho-Mcneil Pharmaceutical, Inc. | Nem peptid szubsztituált benzotiazepinszármazékok, mint vazopresszin antagonisták, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
DK1248604T4 (da) | 2000-01-21 | 2012-05-21 | Novartis Ag | Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler |
CO5271699A1 (es) * | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
WO2001062295A1 (fr) * | 2000-02-24 | 2001-08-30 | Takeda Chemical Industries, Ltd. | Medicaments contenant des ingredients actifs combines |
US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
PE20011184A1 (es) * | 2000-03-16 | 2001-11-15 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
US6562807B2 (en) * | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
GB2363985B (en) | 2000-06-30 | 2004-09-29 | Phytopharm Plc | Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use |
IL144507A0 (en) * | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
US6746856B2 (en) | 2000-08-09 | 2004-06-08 | Pfizer Inc. | Microbial conversion of bicyclic heteroaromatic compounds |
WO2002036066A2 (en) * | 2000-11-01 | 2002-05-10 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising organic vanadium complexes for treatment of ischemia |
US6821960B2 (en) * | 2000-11-17 | 2004-11-23 | Noyo Nordisk Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
US20030037045A1 (en) * | 2001-05-21 | 2003-02-20 | Ian Melhado | Distributed computing environment for recognition of proteomics spectra |
JP4623962B2 (ja) | 2001-10-22 | 2011-02-02 | ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク | タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法 |
US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
JPWO2003037864A1 (ja) * | 2001-10-29 | 2005-02-17 | 日本たばこ産業株式会社 | インドール化合物及びその医薬用途 |
CA2466870A1 (en) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Methods for treating autoimmune disorders, and reagents related thereto |
WO2003045977A2 (en) | 2001-11-26 | 2003-06-05 | Trustees Of Tufts College | Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes |
CN1592749A (zh) * | 2002-01-18 | 2005-03-09 | 辉瑞产品公司 | 用于制备糖原磷酸化酶抑制剂的中间体 |
WO2003063822A2 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
MXPA03000966A (es) | 2002-02-28 | 2003-09-04 | Pfizer Prod Inc | Agentes antidiabeticos. |
GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
DE10215908B4 (de) * | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel |
DE10215907A1 (de) * | 2002-04-11 | 2003-11-06 | Aventis Pharma Gmbh | Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung |
US6683106B2 (en) | 2002-04-15 | 2004-01-27 | Pfizer Inc. | N-(indole-2-carbonyl)-b-alaninamide crystal forms |
AU2003227360A1 (en) * | 2002-04-25 | 2003-11-10 | Yamanouchi Pharmaceutical Co., Ltd. | Novel amide derivatives or salts thereof |
US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
DE10225635C1 (de) * | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
JP4374428B2 (ja) * | 2002-07-11 | 2009-12-02 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 尿素置換されたおよびウレタン置換されたアシル尿素、それらの製造方法および医薬としてのそれらの使用方法 |
UY27967A1 (es) * | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
AU2003274462A1 (en) | 2002-11-07 | 2004-06-07 | Pfizer Products Inc. | N-(indole-2-carbonyl) amides as anti-diabetic agents |
US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
FR2847471B1 (fr) * | 2002-11-25 | 2006-12-29 | Expanscience Lab | Composition comprenant au moins un derive d'acide carbamique ,son utilisation cosmetique et comme medicament |
AU2004212004B2 (en) | 2003-02-13 | 2008-01-10 | Albert Einstein College Of Medicine Of Yeshiva University | Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus |
US20040180845A1 (en) * | 2003-03-13 | 2004-09-16 | Newgard Christopher B. | Methods and compositions for modulating glycogen synthesis and breakdown |
EP1620427A1 (en) * | 2003-04-17 | 2006-02-01 | Pfizer Products Inc. | Carboxamide derivatives as anti-diabetic agents |
MXPA05011702A (es) * | 2003-04-30 | 2006-01-23 | Pfizer Prod Inc | Agentes antidiabeticos. |
MXPA05012547A (es) * | 2003-05-21 | 2006-05-25 | Prosidion Ltd | Inhibidores de amida de acido pirrolopiridina-2-carboxilico de fosforilasa de glucogeno. |
US7405210B2 (en) * | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
KR20070054762A (ko) | 2003-11-12 | 2007-05-29 | 페노믹스 코포레이션 | 헤테로시클릭 보론산 화합물 |
JP2007527904A (ja) | 2004-03-08 | 2007-10-04 | プロシディオン・リミテッド | グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−2−カルボン酸ヒドラジド化合物 |
WO2005085194A2 (en) * | 2004-03-08 | 2005-09-15 | Prosidion Limited | Indole-2-carboxylic acid hydrazides as glycogen phosphorylase inhibitors |
EP1778220A1 (en) | 2004-07-12 | 2007-05-02 | Phenomix Corporation | Constrained cyano compounds |
US7226942B2 (en) | 2004-11-15 | 2007-06-05 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
WO2006053274A2 (en) | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
WO2006055463A2 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
WO2006055435A1 (en) * | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
WO2006059163A1 (en) * | 2004-12-02 | 2006-06-08 | Prosidion Limited | Treatment of diabetes with glycogen phosphorylase inhibitors |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
MY159522A (en) | 2005-09-14 | 2017-01-13 | Takeda Pharmaceuticals Co | Administration of dipeptidyl peptidase inhibitors |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
JP5161793B2 (ja) * | 2006-01-27 | 2013-03-13 | フィブロジェン, インコーポレイテッド | 低酸素症誘導因子(hif)を安定化するシアノイソキノリン化合物 |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
DE102006042147A1 (de) * | 2006-09-06 | 2008-03-27 | Dynamit Nobel Gmbh Explosivstoff- Und Systemtechnik | Hydrochloride von 3-Amino-2-hydroxycarbonsäureamiden |
MEP8509A (en) | 2006-09-07 | 2011-12-20 | Combination treatment for diabetes mellitus | |
WO2008031509A1 (de) * | 2006-09-13 | 2008-03-20 | Sanofi-Aventis | Isoserinderivate als inhibitoren des koagulationsfaktors ixa |
JP5498168B2 (ja) | 2006-12-01 | 2014-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | アテローム性動脈硬化および循環器疾患の治療のためのcetp阻害剤としてのn−((3−ベンジル)−2,2−(ビス−フェニル)−プロパン−1−アミン誘導体 |
CN101765433A (zh) | 2007-03-12 | 2010-06-30 | Zadec私人有限责任公司 | 一种抗糖尿病的红灌木提取物 |
GEP20135957B (en) | 2008-06-19 | 2013-11-11 | Takeda Pharmaceuticals Co | Heterocyclic compound and usage thereof |
AU2010232670B2 (en) | 2009-04-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
RS53176B (en) | 2010-02-03 | 2014-06-30 | Takeda Pharmaceutical Company Limited | KINASE INHIBITORS 1 REGULATING SIGNALS IN APOPTOSIS |
CA2799708A1 (en) | 2010-05-21 | 2011-11-24 | Pfizer Inc. | 2-phenyl benzoylamides |
JP2014513923A (ja) | 2011-03-04 | 2014-06-19 | ファイザー・インク | Edn3様ペプチドおよびその使用 |
JP5885832B2 (ja) | 2011-05-31 | 2016-03-16 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | ネプリライシン阻害剤 |
CA2835216A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
CN103582630B (zh) * | 2011-05-31 | 2016-08-17 | 施万生物制药研发Ip有限责任公司 | 脑啡肽酶抑制剂 |
US20150050371A1 (en) | 2012-03-09 | 2015-02-19 | Biotropics Malaysia Berhad | Extract Formulations of Rhodamnia Cinerea And Uses Thereof |
EP2986599A1 (en) | 2013-04-17 | 2016-02-24 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
CN103497181B (zh) | 2013-09-30 | 2016-03-30 | 承德医学院 | 作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途 |
EA201690938A1 (ru) | 2013-11-05 | 2016-11-30 | Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити | Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания |
US10925881B2 (en) * | 2014-02-28 | 2021-02-23 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
CR20210441A (es) | 2019-01-18 | 2022-03-11 | Astrazeneca Ab | Inhibidores de la pcsk9 y métodos de uso de los mismos |
CN115583908A (zh) * | 2021-07-05 | 2023-01-10 | 西北农林科技大学 | 一种吲哚甲酰胺类化合物及其制备方法和用途 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4764610A (en) | 1981-07-16 | 1988-08-16 | E. I. Du Pont De Nemours And Company | Herbicidal indole sulfonamides |
US4836846A (en) | 1981-07-16 | 1989-06-06 | E. I. Du Pont De Nemours And Company | Herbicidal indole sulfonamides |
NZ202232A (en) | 1981-11-06 | 1985-08-16 | Smithkline Beckman Corp | N-carboxyalkylproline-containing tripeptides and pharmaceutical compositions |
US4933325A (en) | 1985-08-14 | 1990-06-12 | G. D. Searle & Co. | Pyridyl and pyrimidinyl substituted tyrosyl dipeptide amides |
US4902708A (en) | 1985-12-31 | 1990-02-20 | Biomeasure, Inc. | CCK antagonists |
US5089638A (en) | 1986-06-16 | 1992-02-18 | Merck & Co., Inc. | Amino acid analogs as CCK-antagonists |
HU204285B (en) | 1986-10-31 | 1991-12-30 | Pfizer | Process for producing renin-inhibiting polypeptides of small molecule mass and pharmaceutical compositions containing them |
US5034376A (en) | 1986-10-31 | 1991-07-23 | Pfizer Inc. | Nor-statine and nor-cyclostatine polypeptides |
EP0288965A2 (de) | 1987-04-29 | 1988-11-02 | Hoechst Aktiengesellschaft | Peptide mit Phospholipase A2- hemmender Wirkung |
US5128346A (en) | 1987-09-21 | 1992-07-07 | Abbott Laboratories | Derivatives of D-glutamic acid and D-aspartic acid |
US5250517A (en) | 1987-10-06 | 1993-10-05 | Hoffmann-La Roche Inc. | Renin inhibiting compounds |
JPH03503650A (ja) | 1988-04-05 | 1991-08-15 | アボツト・ラボラトリーズ | Cckアンタゴニストとしてのトリプトファン誘導体 |
US5346907A (en) | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
US4904846A (en) | 1988-04-29 | 1990-02-27 | Augustin Oscadal | Oil filled body heater |
US5010089A (en) | 1988-08-12 | 1991-04-23 | Biomeasure, Inc. | CCK antagonists and their use in treating gastrointestinal disorders |
FR2643371B1 (fr) | 1989-02-17 | 1993-11-05 | Roussel Uclaf | Nouveaux derives de l'acide 2-amino pentanedioique, leur procede de preparation et leur application comme medicaments |
US4997950A (en) | 1989-04-20 | 1991-03-05 | Richard Finbar Murphy | Novel C-terminal gastrin antagonists |
IE902238A1 (en) | 1989-06-30 | 1991-01-16 | Abbott Lab | Tetrapeptide type-b cck receptor ligands |
IE902295A1 (en) | 1989-07-07 | 1991-01-16 | Abbott Lab | Amino acid analog cck antagonists |
ES2067635T3 (es) | 1989-12-04 | 1995-04-01 | Searle & Co | Derivados heterociclicos de beta-aminoacidos acilaminodiolicos. |
DE69101835T2 (de) | 1990-02-09 | 1994-08-18 | Rhone Poulenc Rorer Sa | N-phenyl-n-acetamidoglycinamide, ihre herstellung und medikamente, die sie enthalten. |
AU650261B2 (en) | 1990-03-07 | 1994-06-16 | Rhone-Poulenc Rorer S.A. | Derivatives of glycinamide, their preparation and medicaments containing them |
FR2674522B1 (fr) | 1991-03-26 | 1993-07-16 | Lipha | Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant. |
FR2678938B1 (fr) | 1991-07-10 | 1993-10-08 | Rhone Poulenc Rorer Sa | Derives de pyrrolidine, leur preparation et les medicaments les contenant. |
GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
WO1994006755A1 (en) | 1992-09-18 | 1994-03-31 | Japan Tobacco Inc. | Alcohol derivative having renin-inhibiting activity and use thereof |
WO1994007815A2 (en) | 1992-09-25 | 1994-04-14 | Abbott Laboratories | Small peptide anaphylatoxin receptor ligands |
EP0832066B1 (en) * | 1995-06-06 | 2001-09-12 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
-
1995
- 1995-06-06 EP EP95918718A patent/EP0832066B1/en not_active Expired - Lifetime
- 1995-06-06 MX MX9709874A patent/MX9709874A/es not_active IP Right Cessation
- 1995-06-06 SK SK720-96A patent/SK72096A3/sk unknown
- 1995-06-06 PT PT95918718T patent/PT832066E/pt unknown
- 1995-06-06 DE DE69522718T patent/DE69522718T2/de not_active Expired - Fee Related
- 1995-06-06 WO PCT/IB1995/000443 patent/WO1996039385A1/en active IP Right Grant
- 1995-06-06 CA CA002223625A patent/CA2223625C/en not_active Expired - Fee Related
- 1995-06-06 US US08/952,668 patent/US6297269B1/en not_active Expired - Fee Related
- 1995-06-06 DK DK95918718T patent/DK0832066T3/da active
- 1995-06-06 AT AT95918718T patent/ATE205477T1/de not_active IP Right Cessation
- 1995-06-06 AP APAP/P/1996/000817A patent/AP9600817A0/en unknown
- 1995-06-06 ES ES95918718T patent/ES2161291T3/es not_active Expired - Lifetime
- 1995-06-06 AP APAP/P/1996/000816A patent/AP624A/en active
- 1995-06-06 JP JP09500245A patent/JP3068200B2/ja not_active Expired - Fee Related
-
1996
- 1996-05-13 IS IS4345A patent/IS1846B/is unknown
- 1996-05-13 IL IL11823696A patent/IL118236A0/xx unknown
- 1996-05-14 HU HU9601285A patent/HUP9601285A3/hu unknown
- 1996-05-15 MA MA24241A patent/MA23874A1/fr unknown
- 1996-05-17 TN TNTNSN96075A patent/TNSN96075A1/fr unknown
- 1996-05-17 SI SI9600163A patent/SI9600163A/sl not_active IP Right Cessation
- 1996-05-22 DZ DZ960079A patent/DZ2036A1/fr active
- 1996-06-04 BG BG100635A patent/BG62566B1/bg unknown
- 1996-06-04 PL PL96314603A patent/PL314603A1/xx unknown
- 1996-06-04 LV LVP-96-173A patent/LV11614B/en unknown
- 1996-06-04 BR BR9602626A patent/BR9602626A/pt not_active IP Right Cessation
- 1996-06-05 SG SG1996009975A patent/SG45481A1/en unknown
- 1996-06-05 NZ NZ286736A patent/NZ286736A/en unknown
- 1996-06-05 RU RU96111013/14A patent/RU2159613C2/ru not_active IP Right Cessation
- 1996-06-05 NO NO962322A patent/NO307335B1/no not_active IP Right Cessation
- 1996-06-05 AU AU54753/96A patent/AU700887B2/en not_active Ceased
- 1996-06-05 ZA ZA9604646A patent/ZA964646B/xx unknown
- 1996-06-05 CZ CZ19961627A patent/CZ289233B6/cs not_active IP Right Cessation
- 1996-06-05 YU YU34796A patent/YU34796A/sh unknown
- 1996-06-06 HR HR960266A patent/HRP960266B1/xx not_active IP Right Cessation
- 1996-06-06 CO CO96029520A patent/CO4700453A1/es unknown
- 1996-06-06 TR TR96/00478A patent/TR199600478A1/xx unknown
- 1996-06-06 OA OA60836A patent/OA10459A/en unknown
- 1996-06-19 TW TW085107435A patent/TW450961B/zh not_active IP Right Cessation
-
1997
- 1997-12-05 FI FI974437A patent/FI974437A/fi not_active Application Discontinuation
-
2001
- 2001-10-30 GR GR20010401947T patent/GR3037075T3/el not_active IP Right Cessation
-
2002
- 2002-03-05 CN CN02106667A patent/CN1374082A/zh active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL314561A1 (en) | Substituted n-(indolo-2-carbonyl) - glycinamides and their derivatives as antidiabetic agents | |
PL314603A1 (en) | Substituted n-(indolo-2-carbonyl)-beta-alaninamides and their derivatives as antidiabetic agents | |
KR19987002466A (en) | Pyrazol-4-yl-benzoyl derivatives and their use as herbicides | |
ZA964895B (en) | Benzamide derivatives | |
PL313973A1 (en) | 1 n-alkyl-n-arylopyrimidin amines and their derivatives | |
ZA955784B (en) | Amino purine-beta-D-ribofuranuronamide derivatives | |
IL121298A (en) | N-(4-aryl-thiazol-2-yl)-sulphonamide derivatives and their uses | |
GR3029893T3 (en) | N-(Benzofuranazyl)-arylsulphonamides and their analogues useful as endothelin-receptor-antagonists | |
CZ174399A3 (cs) | Derivát benzamidu substituovaný heterocyklickými skupinami a jeho použití | |
PL315970A1 (en) | Substituted triazolynones and their application as herbicides | |
GB9412605D0 (en) | Amide derivatives | |
AU3085895A (en) | N-phenylated amide and urea derivatives | |
PL325279A1 (en) | Pyrazol-4-ylo-benzoyl derivatives and their application as herbicides | |
IL118629A0 (en) | N-Substituted cis-N-propenyl-acetemides their preparation and use | |
AU4021595A (en) | Novel heterocyclic amides | |
ZA964409B (en) | Substituted N-(indole-2-carbonyl)-glycinamides and derivatives as antidiabetic agents. | |
GB9403729D0 (en) | Amine derivatives | |
SI0961774T1 (en) | Pyrazol-4-yl-benzoyl derivatives and their use as herbicides | |
GB9504366D0 (en) | Benzamide derivatives | |
GB9504868D0 (en) | Benzamide derivatives | |
ZA9811077B (en) | N-(4-carbamimido-phenyl)-phenylglycinamid derivatives | |
GB9314349D0 (en) | Amide derivatives | |
GB9314348D0 (en) | Amide derivatives | |
AP9400642A0 (en) | Amine derivatives | |
GB9403730D0 (en) | Amine derivatives |